Circurna develops next‑generation RNA therapeutics using its proprietary ciRNA™ circular RNA platform, which converts therapeutic RNA into a stable circular format for sustained protein expression. The platform combines ribozyme‑mediated circularization, ambient‑stable lipid nanoparticle formulation, and microneedle patch delivery to reduce dosing frequency, lower reactogenicity, and eliminate cold‑chain logistics, enabling broader, patient‑friendly treatment across oncology, fibrosis, autoimmune, infectious and other chronic diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Circurna addresses the limited durability, high reactogenicity, cold‑chain dependence, and frequent dosing requirements of first‑generation linear mRNA therapeutics, which restrict their clinical utility and patient accessibility.
Solution
Circurna’s proprietary ciRNA™ platform converts therapeutic RNA into a circular format that is intrinsically more stable and resistant to degradation, enabling sustained protein production in target cells. The platform incorporates optimized ribozyme‑mediated circularization, high‑purity manufacturing, and low‑immunogenicity design to reduce innate immune responses. Formulated in lipid nanoparticles that remain stable at room temperature, ciRNA™ therapies can be distributed globally without ultra‑cold storage. Additionally, the platform supports injection‑free delivery via microneedle patches, improving patient compliance and expanding access to outpatient and self‑administration settings. By delivering longer‑lasting therapeutic expression at lower or less frequent doses, Circurna aims to broaden the range of treatable diseases, including oncology, fibrosis, autoimmune, infectious, and other chronic conditions.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing RNA‑based therapeutics, as well as clinical programs seeking durable, scalable, and patient‑friendly delivery solutions for oncology, fibrosis, infectious, and chronic disease indications.
Features
- Ribozyme‑catalyzed circular RNA synthesis that yields high‑purity ciRNA with enhanced intracellular stability
- Engineered lipid nanoparticle (LNP) formulation stable at ambient temperature, eliminating cold‑chain logistics
- Injection‑free microneedle patch delivery system for painless, self‑administered dosing
- Reduced innate immune reactogenicity compared with linear mRNA, enabling better tolerability
- Sustained in‑vivo protein expression allowing lower or less frequent dosing across multiple therapeutic modalities
- Platform flexibility to support oncology, fibrosis, autoimmune, infectious disease, and other chronic indications